牛牛AI助手已提取核心信息
Allarity Therapeutics, Inc., a biotechnology company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an offering of securities. The filing, dated January 18, 2024, reports that the company has already sold $400,000 worth of senior convertible promissory notes to one accredited institutional investor. The total offering amount is listed as $1,400,000, with $1,000,000 remaining to be sold. The offering is not being made in connection with a business combination transaction and is expected to last less than one year. Allarity Therapeutics has claimed an exemption under Rule 506(b) and has declined to disclose its revenue range or aggregate net asset value. The company's principal place of business is in Boston, Massachusetts, and the executive officers and directors listed include Thomas Jensen, Joan Brown, Gerald McLaughlin, Laura Benjamin, and Joseph Vazzano. The proceeds from the offering are not intended for payments to any of the named executive officers, directors, or promoters.
Allarity Therapeutics, Inc., a biotechnology company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an offering of securities. The filing, dated January 18, 2024, reports that the company has already sold $400,000 worth of senior convertible promissory notes to one accredited institutional investor. The total offering amount is listed as $1,400,000, with $1,000,000 remaining to be sold. The offering is not being made in connection with a business combination transaction and is expected to last less than one year. Allarity Therapeutics has claimed an exemption under Rule 506(b) and has declined to disclose its revenue range or aggregate net asset value. The company's principal place of business is in Boston, Massachusetts, and the executive officers and directors listed include Thomas Jensen, Joan Brown, Gerald McLaughlin, Laura Benjamin, and Joseph Vazzano. The proceeds from the offering are not intended for payments to any of the named executive officers, directors, or promoters.
在特拉华州注册的生物技术公司Allarity Therapeutics, Inc. 已向美国证券交易委员会提交了D表格的证券豁免发行通知，其中指出了新的证券发行通知。该文件日期为2024年1月18日，报告称，该公司已经向一位合格机构投资者出售了价值40万美元的优先可转换期票。总发行金额列为140万美元，还有100万美元有待出售。此次发行与企业合并交易无关，预计将持续不到一年。Allarity Therapeutics已根据第506（b）条申请豁免，并拒绝透露其收入范围或总净资产价值。该公司的主要营业地点位于马萨诸塞州波士顿，上市的执行官和董事包括托马斯·詹森、琼·布朗、杰拉尔德·麦克劳克林、劳拉·本杰明和约瑟夫·瓦扎诺。此次发行的收益不用于向任何指定的执行官、董事或发起人付款。
在特拉华州注册的生物技术公司Allarity Therapeutics, Inc. 已向美国证券交易委员会提交了D表格的证券豁免发行通知，其中指出了新的证券发行通知。该文件日期为2024年1月18日，报告称，该公司已经向一位合格机构投资者出售了价值40万美元的优先可转换期票。总发行金额列为140万美元，还有100万美元有待出售。此次发行与企业合并交易无关，预计将持续不到一年。Allarity Therapeutics已根据第506（b）条申请豁免，并拒绝透露其收入范围或总净资产价值。该公司的主要营业地点位于马萨诸塞州波士顿，上市的执行官和董事包括托马斯·詹森、琼·布朗、杰拉尔德·麦克劳克林、劳拉·本杰明和约瑟夫·瓦扎诺。此次发行的收益不用于向任何指定的执行官、董事或发起人付款。
有用
没用